Tetraphase Pharmaceuticals Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Tetraphase Pharmaceuticals's estimated annual revenue is currently $1.9M per year.
- Tetraphase Pharmaceuticals received $6.9M in venture funding in July 2017.
- Tetraphase Pharmaceuticals's estimated revenue per employee is $15,000
- Tetraphase Pharmaceuticals's total funding is $144.8M.
- Tetraphase Pharmaceuticals has 126 Employees.
- Tetraphase Pharmaceuticals grew their employee count by 34% last year.
- Tetraphase Pharmaceuticals currently has 3 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase's proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol TTPH. Tetraphase is well positioned to be a major player in the multidrug-resistant arena.keywords:N/A
Number of Employees
Employee Growth %
|Patrick Horn||Chief Marketing Officer|
|Thomas Ouellette||Executive Director Of Marketing And Sales Training|
|Richard Clark||Region Business Director||Email Available|
|Lisa Schechter||Regional Account Manager||Email Available|
|Maureen Montrond||Senior Clinical Project Manager|
|Robert DeVol||Executive Director, Strategy & Market Access||Email Available|
|Michael Greez||Senior Manager, Commercial Operations||Email Available|
|Jamie Rosenvold||Regional Account Manager||Email Available|
|Bruce Bearden||Regional Business Director West Region||Email Available|
Tetraphase Pharmaceuticals News
A look at the shareholders of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) can tell us which group is most powerful. Institutions will often ...
Tetraphase Pharmaceuticals (TTPH) is USA based company. Currently it has a market worth of $21.2M. Using market capitalization to show the ...
On Monday, shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) marked $0.28 per share versus a previous $0.24 closing price.
Tetraphase Pharmaceuticals Funding
|2010-06-02||$45.0M||C||Excel Venture Management||Article|
|2013-11-05||$Undisclosed||Undisclosed||BMO Capital Markets||Article|
|2015-03-13||$173.1M||Undisclosed||BMO Capital Markets||Article|
Tetraphase Pharmaceuticals Executive Hires
|2011-01-25||Patrick Horn||Chief Medical Officer||Article|
|2012-01-06||L Patrick Gage||Chairman||Article|
|2015-03-06||Maria Stahl||SVP/GENERAL COUNSEL||Article|
|2017-10-17||Kam Unninayar||Chief Financial Officer||Article|
|2018-01-03||Larry Tsai||Chief Medical Officer||Article|